Valuation : Apellis Pharmaceuticals, Inc.

Market Cap 5.25B 4.51B 4.22B 3.87B 7.28B 502B 7.3B 49.99B 19.54B 253B 19.72B 19.3B 837B P/E 2027 *
342x
P/E 2028 * 38.3x
Enterprise Value 5.25B 4.51B 4.22B 3.87B 7.28B 502B 7.3B 49.99B 19.54B 253B 19.72B 19.3B 837B EV / Sales 2027 *
5.06x
EV / Sales 2028 * 4.35x
Free-Float
88.57%
Yield 2027 *
-
Yield 2028 * -

Last Transcript : Apellis Pharmaceuticals, Inc.

1 day-0.07%
6 months+95.75%
Current year+63.34%
Current year 16.83
Extreme 16.83
41.14
1 year 16.83
Extreme 16.83
41.14
3 years 16.1
Extreme 16.1
73.8
5 years 16.1
Extreme 16.1
94.75
10 years 11.45
Extreme 11.45
94.75
Manager TitleAgeSince
Chief Operating Officer 56 2009-09-24
Director of Finance/CFO 55 2017-09-30
Chief Tech/Sci/R&D Officer - 2025-08-24
Date Insider Type Main position Quantity % Market Cap.
5/14/26 Tender

Founder

-1,991,703 1.5581%
2/27/26 Free

Director

38,447 0.0304%
2/11/26 Sell

Executive/Senior Manager

368 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-.--%+45.39%+0.64% 5.25B
-0.87%-2.29%+37.61%-2.73% 80.65B
-4.60%+7.09%+468.80%+27.55% 57B
-1.33%+3.03%-20.28%-35.99% 59.9B
+0.76%+3.53%+0.08%+36.18% 53.35B
+0.41%+1.84%+10.29%+171.67% 49.29B
+0.19%+3.34%+62.44%-16.23% 32.73B
-0.30%+0.41%+50.57%+100.03% 25.89B
-0.74%+4.39%+17.93%+207.63% 23.9B
+0.78%+0.47%+61.53%+123.40% 17.07B
Average -0.16%+2.21%+73.44%+61.21% 40.5B
Weighted average by Cap. -0.30%+2.07%+84.24%+46.21%

Financials

2027 *2028 *
Net sales 1.04B 891M 834M 764M 1.44B 99.13B 1.44B 9.88B 3.86B 49.96B 3.9B 3.81B 165B 1.21B 1.04B 971M 890M 1.68B 115B 1.68B 11.5B 4.5B 58.19B 4.54B 4.44B 193B
Net income -34.31M -29.45M -27.57M -25.25M -47.57M -3.28B -47.7M -327M -128M -1.65B -129M -126M -5.47B 90.71M 77.86M 72.9M 66.75M 126M 8.66B 126M 863M 337M 4.37B 341M 333M 14.45B
Net Debt - -
Logo Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Employees
736
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. APLS Stock